Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for vTv Therapeutics (VTVT) over the last 11 years, with Q3 2025 value amounting to $64000.0.

  • vTv Therapeutics' Long-Term Debt Repayments changed N/A to $64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $64000.0, marking a year-over-year decrease of 8646.93%. This contributed to the annual value of $191000.0 for FY2024, which is 6811.35% down from last year.
  • Per vTv Therapeutics' latest filing, its Long-Term Debt Repayments stood at $64000.0 for Q3 2025.
  • vTv Therapeutics' 5-year Long-Term Debt Repayments high stood at $380000.0 for Q4 2021, and its period low was $64000.0 during Q3 2025.
  • Its 5-year average for Long-Term Debt Repayments is $216090.9, with a median of $224000.0 in 2023.
  • In the last 5 years, vTv Therapeutics' Long-Term Debt Repayments crashed by 9536.17% in 2021 and then surged by 20476.19% in 2022.
  • vTv Therapeutics' Long-Term Debt Repayments (Quarter) stood at $380000.0 in 2021, then dropped by 12.37% to $333000.0 in 2022, then fell by 15.32% to $282000.0 in 2023, then plummeted by 32.27% to $191000.0 in 2024, then plummeted by 66.49% to $64000.0 in 2025.
  • Its last three reported values are $64000.0 in Q3 2025, $191000.0 for Q1 2024, and $282000.0 during Q4 2023.